Aridis Pharmaceuticals, Inc.
983 University Avenue
Building B
Los Gatos, CA 95032
United States
408 385 1742
https://www.aridispharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 37
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Eric J. Patzer Ph.D. | Founder & Executive Chairman | 240k | 無 | 1949 |
| Dr. Vu L. Truong Ph.D. | Founder, CEO, Chief Scientific Officer & Director | 631.65k | 無 | 1964 |
| Dr. Hasan Jafri M.D. | Chief Medical Officer | 559.36k | 無 | 1967 |
| Ms. Tamara S. Allen | Vice President of Finance | 無 | 無 | 1967 |
| Mr. Jeffrey J. Fessler Esq., J.D. | Acting General Counsel | 無 | 無 | 1963 |
描述
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
公司管治
截至 無 止，Aridis Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
